Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for June, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- 3 Top-Ranked Consumer ETFs to Buy Now
- Roundtable Top Picks of the Week
- Anatomy of Success: Green Mountain Coffee
- The Mega-Rally Rolls On
- RTI: Prediction Contest: S&P 500 on Dec. 31st
- Industry Rank Analysis: Shifting Into Overdrive
- Biotechnology ETF Investing 101
- 3 Dividend Stocks at Reasonable Prices
- Options Strategies & the Zacks Rank
- AWS 5/21: The Beginning of the End for QE
- PFP 5/21: Below the Surface
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/21/2013
| Company Name | Symbol | %Change |
|---|---|---|
| FEDERAL MOGU | FDML | 5.91% |
| RADIANT LOGI | RLGT | 4.09% |
| ORBOTECH LTD | ORBK | 3.22% |
| NATUS MEDICA | BABY | 3.16% |
| INTEROIL COR | IOC | 3.02% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Endo Health Solutions’ ( ENDP - Analyst Report ) third quarter 2012 earnings (excluding special items) of $1.28 per share beat the Zacks Consensus Estimate of $1.26 and increased 2% from the year-ago period.
Revenues declined 1% in the third quarter of 2012 to $750 million. Revenues were well short of the Zacks Consensus Estimate of $788 million.
Revenues were hurt by lower sales of Endo Health’s painkiller Opana ER (down 36%). Reduced sales of the drug was responsible for Endo Pharmaceuticals division (formerly branded pharmaceuticals), which reflected a 2% decline in sales in the third quarter of 2012. Sales of another pain drug Voltaren Gel dropped 2% to $35.5 million in the reported quarter. Sales of Endo Health’s key pain drug Lidoderm increased 15% in the third quarter of 2012 to $238.3 million.
We remind investors that in August 2012 the US Food and Drug Administration (FDA) cleared Watson Pharmaceuticals’ ( ) generic version of Lidoderm. However, Watson Pharma’s agreement with Endo Health prohibits the former from selling the drug prior to September 15, 2013.
Endo Health’s Qualitest (formerly generics) segment performed well with sales climbing 12% to $166 million in the third quarter of 2012. The increase was driven by favorable pricing and strong demand for the generic drugs. We remind investors that Qualitest Pharmaceuticals (a generic company) was purchased by Endo Health in 2010.
Revenues from the American Medical Systems segment (formerly devices) came in at $113 million in the reported quarter, down 14%. The segment has the following sub-groups: men’s health, women’s health, and benign prostatic hyperplasia therapy. All the sub-groups performed disappointingly in the third quarter of 2012.
Revenues from the HealthTronics segment (formerly services) came in at $54.5 million, up 1%. HealthTronics was acquired by Endo Health in July 2010.
Adjusted operating expenses declined 10.4% to approximately $242 million. The decline was attributable to Endo Health’s prudent cost management.
2012 Projection Lowered
Apart from disclosing its financial results, Endo Health lowered its guidance for 2012. Endo Health now expects to end 2012 with revenues of $3.05 billion (previous guidance: $3.05-$3.175 billion). Endo Health expects to end 2012 with adjusted earnings of $5.00 per share (previous guidance: $5.00-$5.20 per share). The Zacks Consensus Estimate currently pegs earnings at $5.02 per share on revenues of $3.1 billion.
Our Recommendation
We currently have a Neutral recommendation on Endo Health. The stock carries a Zacks #3 Rank (Hold rating) in the short run.
Read the full reports :
Analyst Report on ENDP